Factors influencing the persistence of shunting within 24 hours of catheter occlusion of the ductus arteriosus.
Open Access
- 1 April 1991
- Vol. 65 (4) , 211-212
- https://doi.org/10.1136/hrt.65.4.211
Abstract
The results of the medical treatment of primary pulmonary hypertension are usually very poor. A case of severe primary pulmonary hypertension in chronic heart failure was treated with the calcium antagonist nifedipine, a powerful vasodilator which acts directly on vascular smooth muscle. Nifedipine, administered in a dose of 20 mg sublingually, caused a pronounced fall in pulmonary and systemic vascular resistances (54 and 49%, respectively) and a rise in cardiac output (90.3%). Improvement was maintained over a three-month period. These data suggest that nifedipine can be used in the treatment of this condition.Keywords
This publication has 7 references indexed in Scilit:
- Two-dimensional echocardiographic and color flow Doppler evaluation of ductal occlusion with the Rashkind prosthesis.Circulation, 1989
- Transcatheter closure of patent ductus arteriosus in pediatric patientsThe Journal of Pediatrics, 1989
- Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusionPublished by Elsevier ,1989
- Catheter occlusion of the persistently patent ductus arteriosusThe American Journal of Cardiology, 1988
- Outpatient closure of the patent ductus arteriosus.Circulation, 1988
- Nonsurgical closure of patent ductus arteriosus: clinical application of the Rashkind PDA Occluder System.Circulation, 1987
- Transcatheter closure of patent ductus arteriosusPediatric Cardiology, 1979